Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Affiliations

• ¹ Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium. laurence.buisseret@bordet.be.
• ² Medical Oncology Department, Institut Curie, 75005, Paris, France.
• ³ Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
• ⁴ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, 52074, Cologne, Germany.
• ⁵ Department of General Medical Oncology and Multidisciplinary Breast Unit, Leuven Cancer Institute, University Hospitals Leuven, 3000, Leuven, Belgium.
• ⁶ Medical Oncology Department, Institut Paoli-Calmettes, 13274, Marseille, France.
• ⁷ Medical Oncology Department, Centre Georges-François Leclerc, 21000, Dijon, France.
• ⁸ Department of Oncology, CHU-UCL-Namur - Site Sainte-Elisabeth, 5000, Namur, Belgium.
• ⁹ Medical Oncology Department, Centre Henri Becquerel, 76038, Rouen, France.
• ¹⁰ Department of Oncology, GZA Ziekenhuizen Campus Sint-Augustinus, 2610, Antwerp, Belgium.
• ¹¹ Department of Oncology, Centre Antoine Lacassagne, 06189, Nice, France.
• ¹² Medical Oncology Department, Institut Bergonié, 33000, Bordeaux, France.
• ¹³ Department of Oncology-Hematology, Grand Hôpital de Charleroi - Site Notre Dame, 6000, Charleroi, Belgium.
• ¹⁴ Medical Oncology Department, Cliniques Universitaires Saint-Luc (UCLouvain), 1200, Brussels, Belgium.
• ¹⁵ Department of Oncology, CHU Besançon - Hôpital Jean Minjoz, 25030, Besancon, France.
• ¹⁶ Medical Oncology Department, Clinique Saint-Pierre, 1340, Ottignies-Louvain-la-Neuve, Belgium.
• ¹⁷ Medical Oncology Department, Institut de Cancérologie Strasbourg Europe (ICANS), 67000, Strasbourg, France.
• ¹⁸ Medical Oncology Department, CHU Poitiers, 86000, Poitiers, France.
• ¹⁹ CurePath Laboratory (CHU Tivoli, CHIREC), 6040, Jumet, Belgium.
• ²⁰ Department of Pathology, GZA-ZNA Hospitals, 2610, Antwerp, Belgium.
• ²¹ Centre for Cancer Immunotherapy, Medical Oncology Department, INSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.
• ²² Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, QC, 11290, Canada.